First FA patient dosed in RESTORE-FA trial
On 4th June, the Biotechnology company Design Therapeutics announced that they have dosed the first person with Friedreich’s ataxia (FA) in their phase 1 clinical trial of their drug DT-216P2. […]
First FA patient dosed in RESTORE-FA trial Read More »